GlassScriptPhysician profile
Ishaan Jakhar
NPI 1770100497
$593.45
in general payments reported to CMS, 2019-2025
18 companies · $107 in 2025
The $107 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $11.36 · 2021: $16.32 · 2022: $69.14 · 2023: $237 · 2024: $153 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $496.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $122.38 | 2023 | Dupixent |
| Genzyme Corporation | $100.54 | 2024 | |
| Genentech USA, INC. | $47.46 | 2024-2025 | Xolair |
| Astrazeneca Pharmaceuticals LP | $39.39 | 2023-2025 | Evusheld, Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $32.51 | 2023 | Hyqvia |
| Janssen Pharmaceuticals, INC | $27.31 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $24.89 | 2022 | |
| Lilly USA, LLC | $23.19 | 2025 | Ebglyss |
| Kaleo, INC. | $22.25 | 2023 | Auvi-Q |
| Biocryst US Sales Co., LLC | $21.09 | 2025 | Orladeyo |
| Novartis Pharmaceuticals Corporation | $19.43 | 2023 | |
| Amgen INC. | $18.06 | 2023 | Repatha |
| Grifols USA, LLC | $17.15 | 2024 | Prolastin-C Liquid |
| Pfizer INC. | $16.94 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $16.77 | 2025 | Neffy |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $16.41 | 2024 | Hizentra |
| Amarin Pharma, INC. | $16.32 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.36 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ishaan Jakhar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.